ReviewCancers2025
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.
Yan-You Liao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled itcites it
ReviewCancers2025
Yan-You Liao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.